Oil Prices Hold Steady as Ukraine Tensions and Fed Cut Expectations Support Market 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
BOJ Faces Pressure for Clarity, but Neutral Rate Estimates Likely to Stay Vague 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
ExxonMobil to Shut Older Singapore Steam Cracker Amid Global Petrochemical Downturn 
China’s Services Sector Posts Slowest Growth in Five Months as Demand Softens 
IKEA Launches First New Zealand Store, Marking Expansion Into Its 64th Global Market 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
Wikipedia Pushes for AI Licensing Deals as Jimmy Wales Calls for Fair Compensation 
Amazon Italy Pays €180M in Compensation as Delivery Staff Probe Ends 
GM Issues Recall for 2026 Chevrolet Silverado Trucks Over Missing Owner Manuals 
Visa to Move European Headquarters to London’s Canary Wharf 
Anthropic Reportedly Taps Wilson Sonsini as It Prepares for a Potential 2026 IPO 
Netflix Nearing Major Deal to Acquire Warner Bros Discovery Assets 
Gold Prices Edge Higher as Markets Await Key U.S. PCE Inflation Data 
Asia’s IPO Market Set for Strong Growth as China and India Drive Investor Diversification 
Samsung Biologics is now confirmed to produce Moderna’s COVID-19 vaccines in South Korea. The biotechnology company headquartered in Incheon is said to be working to hasten preparations and begin the production of the shots in the second half of this year.
Confirmation of the vaccine production deal
The Korea Herald reported that Samsung Biologics is preparing its drug manufacturing facility in Songdo, Incheon. This is said to be one of the largest in the world and it is here where the biotech firm will be handling the filling and finishing process of Moderna vaccine production. To be more specific, the mRNA-1273 which is the American pharmaceutical company’s messenger-RNA-based COVID-19 shot.
The Samsung and Moderna agreement was officially signed and this was witnessed by South Korean President Moon Jae In looking. The deal is actually part of the Korean-US vaccine partnership that was one of the agendas at the recent summit that was held in the U.S. last week.
The agreement between Samsung Biologics and Moderna
Samsung Biologics will be filling up vials and packaging them for sale and distribution. The main vaccine content will be coming directly from Moderna and Lonza, its Swiss production partner, and the overall finishing process will be done in Korea.
"This vaccine is paramount to people around the world in the fight against the COVID-19 pandemic, and we truly appreciate our client Moderna for entrusting and choosing to partner with Samsung Biologics for the fill and finish of this important vaccine," Samsung Biologics CEO, John Rim, said in a press release."Due to the high level of urgency in supplying the vaccine to the global population, we have set immediate action plans and schedule to make mRNA-1273 available for commercial distribution in the early second half of 2021."
On the other hand, Moderna’s chief technical operations and quality officer, Juan Andres, said that they are pleased to team up with Samsung Biologics for the fill and finish production. He explained that this arrangement will help them continue to boost their manufacturing capacity outside of the U.S. as they remained committed to beating COVID-19.
Meanwhile, South Korean government officials gladly welcomed the partnership as this is a big opportunity for the country to scale up and be a global factory of vaccines for COVID-19.
